PLATO Foundation launches first medical education activity during 33rd CTRC - AACR Symposium

September 25, 2015

NinePoint's product development strategy is currently focused on novel devices that can significantly improve the access, diagnosis and treatment standards for gastroesophageal reflux disease (GERD) and Barrett's esophagus, conditions that affect more than 19 million Americans annually and that are often precursors to dysplasia and esophageal cancer, as well as many other diseases and conditions. While NinePoint is initially focused on the GI tract, its technology and expertise will allow the company to expand into other indications in the future. NinePoint's initial product introductions will focus on devices that can quickly deliver volumetric, clinically actionable images, and improve upon existing technology that is only able to image a small field of view, requires intravenous contrast and that has long acquisition times. Initially, NinePoint intends to develop proprietary devices that will allow physicians to image the entire distal esophagus, identify and mark abnormal sites in the mucosa and submucosa and perform guided endoscopic biopsies by routine methods during the normal upper endoscopy. This new treatment paradigm could become a more effective replacement for the existing standard of care that requires random biopsies of esophageal mucosa in areas that appear normal when Barrett's esophagus is suspected. Over time, the technology is expected to enable the pathologist to view the tissue in-vivo, provide a real-time diagnosis and allow the gastroenterologist to perform treatment during the same endoscopy visit. NinePoint will work closely with MGH to advance the development of the technology and the company plans to introduce the first device prototypes for use in clinical trials in 2011.

"Previous generations of OCT technology produced precise, but small images with long image acquisition times that rendered them unfeasible for clinical use. For the first time, technology exists that can open the door to utilizing real-time images for immediate diagnosis and treatment," said Brett E. Bouma, Ph.D., of the Wellman Center for Photomedicine at Massachusetts General Hospital and co-developer of the OFDI platform.

"Exclusive access to MGH's broad and deep portfolio of imaging patents is a significant milestone for NinePoint and we are honored that MGH has chosen to partner with us on the development of this important technology," said Charles Carignan, M.D., president and chief executive officer of NinePoint Medical. "We believe our technology development roadmap will support the commercialization of novel medical devices that can significantly streamline the time and cost required to access, diagnose and facilitate treatment of pre-cancerous and cancerous cells. We are excited to be a pioneer in this convergence that we believe will positively impact patient care. While we are currently focused on the GI tract, we believe that our high resolution optical imaging platform may have broad applicability in other therapeutic areas, which we intend to explore in the future."

SOURCE NinePoint Medical, Inc.